Skip to Main Content
Contribute Try STAT+ Today

By the time patients with multiple myeloma have gone through four or five different therapies, the outlook for any new treatment is dim. Most interventions offer these patients only a scant few more months of life. But new data on a Janssen CAR-T therapy called cilta-cel suggests the treatment might help halt progression of the disease for nearly two years.

“That, for our patients, is something that we’ve never seen before from any other single agent,” said Krina Patel, an oncologist at the MD Anderson Cancer Center who has served on an advisory board for Janssen but did not work on cilta-cel. “We might get a few months for most patients with a new agent, but 21.8 months without any therapy is fantastic.”  

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment